Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.58 |
| ▸ | KIF11 | P52732 | 14/20 | 0.53 |
| ▸ | HNF4A | P41235 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5533184 | 0.82 | GAA (0.81) | GAAKIF11HNF4AHPGDSMN1; SMN2 | |
| SCHEMBL14435023 | 0.81 | KIF11 (0.40) | GAAKIF11HNF4ANLRP3MAPT | |
| SCHEMBL14435020 | 0.81 | KIF11 (0.40) | GAAKIF11HNF4ANLRP3MAPT | |
| SCHEMBL14435016 | 0.78 | MAPT (0.49) | GAAHPGDKDM4EALDH1A1TP53 | |
| SCHEMBL14435015 | 0.78 | MAPT (0.49) | GAAHPGDKDM4EALDH1A1TP53 | |
| SCHEMBL14435013 | 0.78 | MAPT (0.49) | GAAHPGDKDM4EALDH1A1TP53 | |
| SCHEMBL14435014 | 0.78 | MAPT (0.49) | GAAHPGDKDM4EALDH1A1TP53 | |
| SCHEMBL28162395 | 0.77 | KIF11 (0.86) | GAAKIF11HNF4ANLRP3 | |
| SCHEMBL5514635 | 0.76 | GAA (0.64) | GAAKIF11HNF4ANLRP3 | |
| SCHEMBL15321012 | 0.72 | GAA (0.69) | GAAKIF11HNF4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179172-A1 | Positive modulators of nicotinic acetylcholine receptors | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179172-A1 | Positive modulators of nicotinic acetylcholine receptors | CHRNA1, CHRNA2, CHRM1 | GAA 2936/4885KIF11 3859/4885HNF4A 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.